Nutra Pharma Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NPHC research report →
Price Chart
About the company
Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications. The company primarily targets the U.
- CEO
- Michael D. Flax
- IPO
- 2001
- Employees
- 7
- HQ
- Boca Raton, FL, US
Get TickerSpark's AI analysis on NPHC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $715.97K
- P/E
- -0.12
- PEG
- 0.00
- P/S
- 3.46
- P/B
- -0.04
- EV/EBITDA
- -8.12
- Div Yield
- 0.00%
- Gross Margin
- 50.38%
- Op Margin
- -790.74%
- Net Margin
- -2618.79%
- ROE
- 30.26%
- ROIC
- 18.47%
Latest fiscal year · YoY change
- Revenue
- $385.31K+0.0%
- Gross Profit
- $196.63K+0.0%
- Op Income
- $-1,462,338
- Net Income
- $-2,047,392+0.0%
- EPS
- $-0.00+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.90
- RSI (14)
- 42
- Avg Volume
- 297.25K
No earnings-call transcripts are available for NPHC yet.
- Free Float
- 99.0%
- Shares Outstanding
- 7.16B
- Float Shares
- 7.09B
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 21 | DEITSCH RIK J | other | 0 |
| Dec 19, 16 | DEITSCH RIK J | buy | 15,000,000 |
| Jul 5, 16 | DEITSCH RIK J | buy | 15,000,000 |
| Jun 28, 16 | DEITSCH RIK J | other | 4,000,000 |
| Jun 13, 15 | DEITSCH RIK J | other | 4,000,000 |
| Dec 11, 14 | DEITSCH RIK J | other | 506,900 |
| Apr 10, 14 | DEITSCH RIK J | buy | 1,250,000 |
| Oct 30, 17 | DEITSCH RIK J | other | 3,000,000 |
| Jun 17, 16 | ORAN DAN | other | 0 |
| Jun 17, 16 | ORAN DAN | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NPHC coverage
Recent articles, reports, and earnings notes.
No research on NPHC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NPHC report →Nutra Pharma (OTCMKTS:NPHC) versus XOMA Royalty (NASDAQ:XOMA) Head-To-Head Review
defenseworld.net · Jan 18
REPORT: Buganda, Ankole & Busoga Regions Getting Highest Remittances From Abroad
watchdoguganda.com · Oct 21
Why SPA Mutyabule believes census is a good tool in combating poverty in Busoga
watchdoguganda.com · May 13
Nutra Pharma Corp. Reaches Settlement with SEC
prismmediawire.com · Mar 22
Nutra Pharma Corp. Reaches Settlement with SEC
globenewswire.com · Mar 22
Nutra Pharma Provides Business and Compliance Updates
globenewswire.com · Jul 26
Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures
globenewswire.com · Jul 23
Nutra Pharma Engages Government Affairs Consulting Firm
globenewswire.com · Jul 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.